Lowers the risk of stroke and systemic embolism. ANDA 213879, held by Msn. Dabigatran Etexilate Mesylate.
As of Nov 16, 2026, ANDA 213879 (Dabigatran Etexilate Mesylate), held by Msn, was first approved by FDA on Aug 12, 2024, with 1 approved supplement and 0 published complete response letters.
Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery 1.
| Aug 12, 2024 | Original application | Approved | None posted |
| May 22, 2024 | Original application | Approved |
| Dabigatran Etexilate MesylateEQ 75MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 150MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 110MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Oct 1, 2024 | Supplement 2Manufacturing | Approved | None posted |
| Aug 12, 2024 | Original application | Approved | None posted |
| May 22, 2024 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters